Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 17:17:155-163.
doi: 10.2147/TCRM.S293879. eCollection 2021.

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease

Taisuke Ishii  1 , Tetsuhiro Tanaka  1 , Masaomi Nangaku  1
Affiliations
Review

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease

Taisuke Ishii et al. Ther Clin Risk Manag. .

Abstract

Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxia-inducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.

Keywords: erythropoietin; hypoxia-inducible factor; iron; prolyl hydroxylase domain.

PubMed Disclaimer

Conflict of interest statement

M.N. has received research grant from JT, and Kyowa Kirin Co. Ltd., and personal fees from GlaxoSmithKline, Astellas, Mitsubishi Tanabe Pharma Corporation, Bayer Yakuhin Ltd., Torii Pharmaceutical Co. Ltd, and AstraZeneca, outside the submitted work. T.T. has received research grant from JT and Bayer. T.I. declared no conflicts of interest. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252. doi:10.1016/S0140-6736(16)32064-5 - DOI - PubMed
    1. Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394–410. - PMC - PubMed
    1. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16(6):1803–1810. doi:10.1681/ASN.2004070597 - DOI - PubMed
    1. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084. doi:10.1056/NEJMoa062276 - DOI - PubMed
    1. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(1):33–38. doi:10.2215/CJN.00630208 - DOI - PMC - PubMed

LinkOut - more resources